TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03075696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
Study: NCT00097474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03300154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framing (SMS)
Description: After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
Study: NCT04462211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of management pharmacological protocol of constipation
Description: first 48 hours:~* polyethylene glycol 3350 (about 17 grams) 1 every 8 hours enterally.~* Patients who have vomiting and / or gastric residue greater than 500 mL (in a timely measurement every 6 hours) will also be given domperidone 10 mg every 8 hours intravenously.~* Patients who have excessive abdominal distension will be administered in addition, levosulpiride 25 mg every 8 hours intravenously.~  48 hour evaluation:~* Patients who do not have bowel movements will be administered lactulose or sodium phosphate enema.~* For patients who do not have a bowel movement, administration of neostigmine intravenously or of naloxone enterally will be evaluated.~* Every patient who uses one or more prokinetics will have an electrocardiogram.~* Any patient who has bowel movements during management, doses of polyethylene glycol 3350 will be adjusted according to the daily goal of bowel movements, the days of treatment of the prokinetics will be adjusted, for a maximum of 5 consecutive days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of bundle of prevention and non-pharmacological management
Description: Bundle of prevention:~* Start early enteral nutrition.~* Optimize and / or decrease opioid doses.~* Start early mobilization.~Non-pharmacological management bundle~* Select laxative and/or prokinetic/s to manage constipation.~* Optimize and / or decrease doses of opioids and sedatives.~* Start early mobilization.~* Pharmacological reconciliation.
Study: NCT01931696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Description: 100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: 100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
Study: NCT03703869

Intervention type: DRUG
Intervention: Insulin glargine (U300)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection
Study: NCT02516943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patient's ABGs were test according to a 4 - hour routine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guideline
Description: The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
Study: NCT00797472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mabHD
Description: An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
Study: NCT04074616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Dose
Description: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Low dose
Description: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
Study: NCT03294720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bio-ACL
Description: ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: amnion wrap and BMAC
Description: amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
Study: NCT01539018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib plus tegafur-uracil
Description: Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
Study: NCT00797472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD
Description: A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
Study: NCT00602953

Intervention type: OTHER
Intervention: No intervention planned.
Description: This is a cross-sectional observational study, no intervention is planned.

Intervention type: OTHER
Intervention: No intervention planned.
Description: This is a cross-sectional observational study, no intervention is planned.

Intervention type: OTHER
Intervention: No intervention planned.
Description: This is a cross-sectional observational study, no intervention is planned.

Intervention type: OTHER
Intervention: No intervention planned.
Description: This is a cross-sectional observational study, no intervention is planned.

Intervention type: OTHER
Intervention: No intervention planned.
Description: This is a cross-sectional observational study, no intervention is planned.
Study: NCT04465331

Intervention type: OTHER
Intervention: Questionnaires
Description: completion of Exercise Adherence Rating Scale (EARS)
Study: NCT02233816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of quadrivalent VLP vaccine
Description: A single low dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose of quadrivalent VLP vaccine
Description: A single medium dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of quadrivalent VLP vaccine
Description: A single high dose of quadrivalent VLP vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo
Study: NCT02122393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Study: NCT03031626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medical Air vs Oxygen
Description: Medical Air/Oxygen will be given

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medical Air vs Oxygen
Description: Medical Air/Oxygen will be given
Study: NCT04621825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.
Description: Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection.
Study: NCT04073290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 550 milligram Oral Tablet [XIFAXAN]
Description: Rifaximin 550 milligram b.i.d. 72 hours before TIPS placement till 3 months post-TIPS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactulose 667 milligram/milliliter Oral Solution
Description: Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose 667 milligram/milliliter Oral Solution
Description: Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
Study: NCT04544969

Intervention type: DRUG
Intervention: cisplatin-based chemotherapy
Description: GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge.
Study: NCT04171219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talabostat Mesylate
Description: Given PO
Study: NCT03927833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy lights
Description: Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy lights
Description: Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.
Study: NCT02728557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive-Expressive Therapy
Description: Supportive-expressive psychotherapy for depressive disorder for 16 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Therapy
Description: Supportive psychotherapy for depressive disorder for 16 weeks.
Study: NCT01718743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03516708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Drug provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Drug provided.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiation therapy
Description: Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short-course radiation therapy
Description: Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiation therapy
Description: Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
Study: NCT03871309

Intervention type: DEVICE
Intervention: Tigertriever
Description: Mechanical Thrombectomy
Study: NCT03526393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Survey training equipment
Description: The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attack and serve training equipment
Description: The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pass training equipment
Description: The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
Study: NCT02834117

Intervention type: OTHER
Group type: OTHER
Intervention: natural cycle
Description: Ovulation is not induced by drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moderate ovarian stimulation
Description: Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
Study: NCT00999635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insole
Description: Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
Study: NCT03624478

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study: NCT03778749

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TOF measurements
Description: The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TOF measurements
Description: The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
Study: NCT03516708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX chemotherapy
Description: Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX chemotherapy
Description: Standard of care
Study: NCT02122393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Study: NCT00003325

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel lymph node mapping
Description: Sentinel lymph node mapping
Study: NCT03281486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA formulation Oral Spray
Description: It is an HA formulation of FDA listed ingredients

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation without the active ingredients
Study: NCT00468325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-slice computed tomography
Description: Patient receives a CT scan (multi-slice computed tomography) of the heart.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rest-stress Nuclear Myocardial Perfusion Imaging
Description: Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-slice Computed Tomography
Description: Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
Study: NCT04567225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Glargine
Description: A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Late Glargine
Description: A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV insulin infusion
Description: Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV insulin infusion
Description: Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluid and electrolytes replacement
Description: The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
Study: NCT03516708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX chemotherapy
Description: Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX chemotherapy
Description: Standard of care
Study: NCT03778749

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TOF measurements
Description: The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
Study: NCT03292549

Intervention type: PROCEDURE
Intervention: Robotic partial surgery
Description: Robotic partial surgery
Study: NCT00292279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil emulsion (Omegaven )
Description: Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long-chain triglyceride
Description: the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
Study: NCT01353443

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optilene® Mesh Elastic
Description: A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
Study: NCT00499512

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).